546 related articles for article (PubMed ID: 18578523)
21. Serum markers for prostate cancer: a rational approach to the literature.
Steuber T; O'Brien MF; Lilja H
Eur Urol; 2008 Jul; 54(1):31-40. PubMed ID: 18243505
[TBL] [Abstract][Full Text] [Related]
22. A cell proteomic approach for the detection of secretable biomarkers of invasiveness in oral squamous cell carcinoma.
Mlynarek AM; Balys RL; Su J; Hier MP; Black MJ; Alaoui-Jamali MA
Arch Otolaryngol Head Neck Surg; 2007 Sep; 133(9):910-8. PubMed ID: 17875858
[TBL] [Abstract][Full Text] [Related]
23. Urinary markers for prostate cancer.
Downes MR; Byrne JC; Pennington SR; Dunn MJ; Fitzpatrick JM; Watson RW
BJU Int; 2007 Feb; 99(2):263-8. PubMed ID: 17092277
[TBL] [Abstract][Full Text] [Related]
24. New circulating biomarkers for prostate cancer.
Bensalah K; Lotan Y; Karam JA; Shariat SF
Prostate Cancer Prostatic Dis; 2008; 11(2):112-20. PubMed ID: 17998918
[TBL] [Abstract][Full Text] [Related]
25. Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases.
Selander KS; Brown DA; Sequeiros GB; Hunter M; Desmond R; Parpala T; Risteli J; Breit SN; Jukkola-Vuorinen A
Cancer Epidemiol Biomarkers Prev; 2007 Mar; 16(3):532-7. PubMed ID: 17372249
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of plasma interleukin-8 concentration in patients with prostate cancer and benign prostate hyperplasia.
Dehghani M; Mostafavi-Pour Z; Lotfi M; Shakeri S
Iran J Immunol; 2009 Jun; 6(2):92-8. PubMed ID: 19561378
[TBL] [Abstract][Full Text] [Related]
27. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins.
Peracaula R; Tabarés G; Royle L; Harvey DJ; Dwek RA; Rudd PM; de Llorens R
Glycobiology; 2003 Jun; 13(6):457-70. PubMed ID: 12626390
[TBL] [Abstract][Full Text] [Related]
28. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
29. Proteomic analysis of dunning prostate cancer cell lines with variable metastatic potential using SELDI-TOF.
Gretzer MB; Chan DW; van Rootselaar CL; Rosenzweig JM; Dalrymple S; Mangold LA; Partin AW; Veltri RW
Prostate; 2004 Sep; 60(4):325-31. PubMed ID: 15264244
[TBL] [Abstract][Full Text] [Related]
30. Detection of prostate-specific antigen coupled to immunoglobulin M in prostate cancer patients.
Beneduce L; Prayer-Galetti T; Giustinian AM; Gallotta A; Betto G; Pagano F; Fassina G
Cancer Detect Prev; 2007; 31(5):402-7. PubMed ID: 18035503
[TBL] [Abstract][Full Text] [Related]
31. Proteomics-based identification of secreted protein dihydrodiol dehydrogenase as a novel serum markers of non-small cell lung cancer.
Huang LJ; Chen SX; Huang Y; Luo WJ; Jiang HH; Hu QH; Zhang PF; Yi H
Lung Cancer; 2006 Oct; 54(1):87-94. PubMed ID: 16876904
[TBL] [Abstract][Full Text] [Related]
32. Analysis of prostate cancer by proteomics using tissue specimens.
Liu AY; Zhang H; Sorensen CM; Diamond DL
J Urol; 2005 Jan; 173(1):73-8. PubMed ID: 15592032
[TBL] [Abstract][Full Text] [Related]
33. Presence and enzymatic activity of prostate-specific antigen in archival prostate cancer samples.
Vukmirovic-Popovic S; Escott NG; Duivenvoorden WC
Oncol Rep; 2008 Oct; 20(4):897-903. PubMed ID: 18813833
[TBL] [Abstract][Full Text] [Related]
34. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
35. Cancer biomarkers: knowing the present and predicting the future.
Chatterjee SK; Zetter BR
Future Oncol; 2005 Feb; 1(1):37-50. PubMed ID: 16555974
[TBL] [Abstract][Full Text] [Related]
36. Identification of proteins secreted by head and neck cancer cell lines using LC-MS/MS: Strategy for discovery of candidate serological biomarkers.
Ralhan R; Masui O; Desouza LV; Matta A; Macha M; Siu KW
Proteomics; 2011 Jun; 11(12):2363-76. PubMed ID: 21598386
[TBL] [Abstract][Full Text] [Related]
37. Proteome profile of the MCF7 cancer cell line: a mass spectrometric evaluation.
Sarvaiya HA; Yoon JH; Lazar IM
Rapid Commun Mass Spectrom; 2006; 20(20):3039-55. PubMed ID: 16986208
[TBL] [Abstract][Full Text] [Related]
38. Blood biomarkers for prostate cancer detection and prognosis.
Shariat SF; Karam JA; Roehrborn CG
Future Oncol; 2007 Aug; 3(4):449-61. PubMed ID: 17661720
[TBL] [Abstract][Full Text] [Related]
39. Entering a new era of rational biomarker discovery for early detection of melanoma metastases: secretome analysis of associated stroma cells.
Paulitschke V; Kunstfeld R; Mohr T; Slany A; Micksche M; Drach J; Zielinski C; Pehamberger H; Gerner C
J Proteome Res; 2009 May; 8(5):2501-10. PubMed ID: 19222175
[TBL] [Abstract][Full Text] [Related]
40. Biochemical markers for monitoring response to therapy: evidence for higher bone specificity by a novel marker compared with routine markers.
Leeming DJ; Hegele A; Byrjalsen I; Hofmann R; Qvist P; Karsdal MA; Schrader AJ; Wagner R; Olbert P
Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1269-76. PubMed ID: 18483350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
